Unibest
← Back to patent-cliff list

Clascoterone

Tier C — Watch / trade

Clascoterone

Intrepid Therapeutics Inc
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:AR

Brand:Winlevi, Breezula

Indications (approved):Acne vulgaris

Regional status

US
Approved
2020-08-26
EU
Approved
2025-11-17
China
Phase III
2024-05-20
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 1 · Total yield 0.437 g
CB-0301-00119608-30-1API · Clascoterone
CodeCAS No.Intermediate
CB-0301-00119608-30-1(8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3-oxo-17-(2-(propionyloxy)acetyl)-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl propionate

Frequently asked questions

What are the approved indications of Clascoterone?

Approved indications include: Acne vulgaris.

When does the Clascoterone patent expire?

No public expiry year is available for Clascoterone yet; this page updates once verified.

How many synthesis routes are recorded for Clascoterone?

1 synthesis routes are recorded; the shortest is 1 steps with 0.437 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Clascoterone intermediates?

All intermediates in Clascoterone routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Clascoterone intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29